Related Experiment Videos
Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with
A Martens1, R A Janssen, D T Sleijfer
1Department of Clinical Immunology, University Hospital Groningen, The Netherlands.
British Journal of Cancer
|May 1, 1993
Abstract:
Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.